PDS Biotechnology (PDSB) Competitors $1.16 +0.13 (+12.62%) Closing price 04:00 PM EasternExtended Trading$1.16 0.00 (-0.09%) As of 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PDSB vs. EDIT, ALEC, CHRS, CNTN, and HELPShould you buy PDS Biotechnology stock or one of its competitors? MarketBeat compares PDS Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PDS Biotechnology include Editas Medicine (EDIT), Alector (ALEC), Coherus Oncology (CHRS), Hillstream Biopharma (CNTN), and Cybin (HELP). These companies are all part of the "pharmaceutical products" industry. PDSB vs. EDITPDSB vs. ALECPDSB vs. CHRSPDSB vs. CNTNPDSB vs. HELPHow does PDS Biotechnology compare to Editas Medicine?Editas Medicine (NASDAQ:EDIT) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends. Do insiders and institutionals hold more shares of EDIT or PDSB? 71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 3.1% of Editas Medicine shares are owned by insiders. Comparatively, 9.2% of PDS Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, EDIT or PDSB? Editas Medicine has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market. Does the media prefer EDIT or PDSB? In the previous week, PDS Biotechnology had 7 more articles in the media than Editas Medicine. MarketBeat recorded 9 mentions for PDS Biotechnology and 2 mentions for Editas Medicine. PDS Biotechnology's average media sentiment score of 0.67 beat Editas Medicine's score of 0.65 indicating that PDS Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PDS Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is EDIT or PDSB more profitable? PDS Biotechnology has a net margin of 0.00% compared to Editas Medicine's net margin of -281.59%. PDS Biotechnology's return on equity of -346.02% beat Editas Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Editas Medicine-281.59% -677.39% -58.25% PDS Biotechnology N/A -346.02%-102.36% Do analysts rate EDIT or PDSB? Editas Medicine currently has a consensus price target of $5.40, suggesting a potential upside of 102.25%. PDS Biotechnology has a consensus price target of $9.00, suggesting a potential upside of 675.86%. Given PDS Biotechnology's higher possible upside, analysts clearly believe PDS Biotechnology is more favorable than Editas Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Editas Medicine 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57PDS Biotechnology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has preferable valuation and earnings, EDIT or PDSB? PDS Biotechnology has lower revenue, but higher earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEditas Medicine$40.52M6.45-$160.06M-$1.23N/APDS BiotechnologyN/AN/A-$34.50M-$0.67N/A SummaryPDS Biotechnology beats Editas Medicine on 9 of the 15 factors compared between the two stocks.How does PDS Biotechnology compare to Alector?PDS Biotechnology (NASDAQ:PDSB) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment. Does the media refer more to PDSB or ALEC? In the previous week, PDS Biotechnology had 9 more articles in the media than Alector. MarketBeat recorded 9 mentions for PDS Biotechnology and 0 mentions for Alector. PDS Biotechnology's average media sentiment score of 0.67 beat Alector's score of 0.00 indicating that PDS Biotechnology is being referred to more favorably in the media. Company Overall Sentiment PDS Biotechnology Positive Alector Neutral Is PDSB or ALEC more profitable? PDS Biotechnology has a net margin of 0.00% compared to Alector's net margin of -680.83%. Alector's return on equity of -295.17% beat PDS Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets PDS BiotechnologyN/A -346.02% -102.36% Alector -680.83%-295.17%-40.95% Which has more risk and volatility, PDSB or ALEC? PDS Biotechnology has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market. Comparatively, Alector has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market. Which has preferable earnings and valuation, PDSB or ALEC? PDS Biotechnology has higher earnings, but lower revenue than Alector. Alector is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPDS BiotechnologyN/AN/A-$34.50M-$0.67N/AAlector$21.05M11.66-$142.93M-$1.19N/A Do institutionals and insiders believe in PDSB or ALEC? 26.8% of PDS Biotechnology shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 9.2% of PDS Biotechnology shares are owned by company insiders. Comparatively, 8.3% of Alector shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts rate PDSB or ALEC? PDS Biotechnology currently has a consensus price target of $9.00, indicating a potential upside of 675.86%. Alector has a consensus price target of $3.63, indicating a potential upside of 64.03%. Given PDS Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe PDS Biotechnology is more favorable than Alector.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PDS Biotechnology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Alector 2 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.13 SummaryPDS Biotechnology beats Alector on 10 of the 15 factors compared between the two stocks.How does PDS Biotechnology compare to Coherus Oncology?PDS Biotechnology (NASDAQ:PDSB) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk. Which has more risk & volatility, PDSB or CHRS? PDS Biotechnology has a beta of 1.51, meaning that its share price is 51% more volatile than the broader market. Comparatively, Coherus Oncology has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market. Is PDSB or CHRS more profitable? Coherus Oncology has a net margin of 397.30% compared to PDS Biotechnology's net margin of 0.00%. Coherus Oncology's return on equity of -198.90% beat PDS Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets PDS BiotechnologyN/A -346.02% -102.36% Coherus Oncology 397.30%-198.90%-46.65% Do institutionals & insiders hold more shares of PDSB or CHRS? 26.8% of PDS Biotechnology shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 9.2% of PDS Biotechnology shares are owned by company insiders. Comparatively, 8.1% of Coherus Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has preferable earnings and valuation, PDSB or CHRS? Coherus Oncology has higher revenue and earnings than PDS Biotechnology. PDS Biotechnology is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPDS BiotechnologyN/AN/A-$34.50M-$0.67N/ACoherus Oncology$42.17M5.74$168.02M$1.670.94 Do analysts recommend PDSB or CHRS? PDS Biotechnology presently has a consensus target price of $9.00, suggesting a potential upside of 675.86%. Coherus Oncology has a consensus target price of $8.67, suggesting a potential upside of 452.02%. Given PDS Biotechnology's higher possible upside, research analysts clearly believe PDS Biotechnology is more favorable than Coherus Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PDS Biotechnology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Coherus Oncology 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the media favor PDSB or CHRS? In the previous week, PDS Biotechnology had 9 more articles in the media than Coherus Oncology. MarketBeat recorded 9 mentions for PDS Biotechnology and 0 mentions for Coherus Oncology. PDS Biotechnology's average media sentiment score of 0.67 beat Coherus Oncology's score of 0.33 indicating that PDS Biotechnology is being referred to more favorably in the media. Company Overall Sentiment PDS Biotechnology Positive Coherus Oncology Neutral SummaryCoherus Oncology beats PDS Biotechnology on 10 of the 15 factors compared between the two stocks.How does PDS Biotechnology compare to Hillstream Biopharma?PDS Biotechnology (NASDAQ:PDSB) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation. Is PDSB or CNTN more profitable? Hillstream Biopharma's return on equity of -31.50% beat PDS Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets PDS BiotechnologyN/A -346.02% -102.36% Hillstream Biopharma N/A -31.50%-24.72% Do analysts rate PDSB or CNTN? PDS Biotechnology presently has a consensus price target of $9.00, indicating a potential upside of 675.86%. Given PDS Biotechnology's stronger consensus rating and higher possible upside, equities analysts clearly believe PDS Biotechnology is more favorable than Hillstream Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PDS Biotechnology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has preferable valuation and earnings, PDSB or CNTN? PDS Biotechnology is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPDS BiotechnologyN/AN/A-$34.50M-$0.67N/AHillstream BiopharmaN/AN/A-$35.92M-$1.97N/A Do insiders and institutionals believe in PDSB or CNTN? 26.8% of PDS Biotechnology shares are held by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are held by institutional investors. 9.2% of PDS Biotechnology shares are held by insiders. Comparatively, 6.7% of Hillstream Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, PDSB or CNTN? PDS Biotechnology has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.44, indicating that its stock price is 44% more volatile than the broader market. Does the media favor PDSB or CNTN? In the previous week, PDS Biotechnology had 4 more articles in the media than Hillstream Biopharma. MarketBeat recorded 9 mentions for PDS Biotechnology and 5 mentions for Hillstream Biopharma. PDS Biotechnology's average media sentiment score of 0.67 beat Hillstream Biopharma's score of -0.14 indicating that PDS Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PDS Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hillstream Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryPDS Biotechnology beats Hillstream Biopharma on 10 of the 13 factors compared between the two stocks.How does PDS Biotechnology compare to Cybin?Cybin (NASDAQ:HELP) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations. Do analysts prefer HELP or PDSB? Cybin presently has a consensus target price of $58.75, suggesting a potential upside of 1,177.17%. PDS Biotechnology has a consensus target price of $9.00, suggesting a potential upside of 675.86%. Given Cybin's stronger consensus rating and higher possible upside, equities analysts plainly believe Cybin is more favorable than PDS Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cybin 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00PDS Biotechnology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has preferable valuation & earnings, HELP or PDSB? PDS Biotechnology is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCybinN/AN/A-$81.31M-$4.23N/APDS BiotechnologyN/AN/A-$34.50M-$0.67N/A Is HELP or PDSB more profitable? Cybin's return on equity of -59.98% beat PDS Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets CybinN/A -59.98% -50.80% PDS Biotechnology N/A -346.02%-102.36% Which has more risk and volatility, HELP or PDSB? Cybin has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market. Does the media prefer HELP or PDSB? In the previous week, PDS Biotechnology had 9 more articles in the media than Cybin. MarketBeat recorded 9 mentions for PDS Biotechnology and 0 mentions for Cybin. PDS Biotechnology's average media sentiment score of 0.67 beat Cybin's score of 0.00 indicating that PDS Biotechnology is being referred to more favorably in the news media. Company Overall Sentiment Cybin Neutral PDS Biotechnology Positive Do institutionals & insiders have more ownership in HELP or PDSB? 17.9% of Cybin shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 15.0% of Cybin shares are owned by insiders. Comparatively, 9.2% of PDS Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryCybin beats PDS Biotechnology on 7 of the 13 factors compared between the two stocks. Get PDS Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PDSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PDSB vs. The Competition ExportMetricPDS BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$64.75M$3.36B$6.34B$12.28BDividend YieldN/A2.32%2.80%5.36%P/E Ratio-1.7319.0220.9225.48Price / SalesN/A278.81521.1573.33Price / CashN/A125.3543.1855.00Price / Book16.576.909.987.01Net Income-$34.50M$24.23M$3.55B$335.16M7 Day Performance-18.88%0.65%0.40%-0.30%1 Month Performance-13.43%-0.55%-0.04%1.14%1 Year Performance-26.58%63.42%34.95%34.69% PDS Biotechnology Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PDSBPDS Biotechnology3.4091 of 5 stars$1.16+12.6%$9.00+675.9%-36.8%$64.75MN/AN/A20Analyst RevisionEDITEditas Medicine3.4716 of 5 stars$2.48-2.2%$5.40+118.2%+58.5%$240.37M$40.52MN/A230ALECAlector3.0568 of 5 stars$2.07-2.4%$3.63+75.1%+54.7%$227.61M$21.05MN/A270CHRSCoherus Oncology3.1338 of 5 stars$1.49-0.3%$8.67+483.6%+85.0%$225.98M$46.88M0.88330CNTNHillstream Biopharma0.6161 of 5 stars$3.16-3.0%N/AN/A$221.63MN/AN/A2 Related Companies and Tools Related Companies EDIT Competitors ALEC Competitors CHRS Competitors CNTN Competitors HELP Competitors TRDA Competitors RNA Competitors TNXP Competitors FHTX Competitors LENZ Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PDSB) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PDS Biotechnology Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share PDS Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
